TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01493271
Drug: RO5093151
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral doses twice daily for up to 28 days
Study: NCT00099983
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01107782
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50mg tid
Study: NCT02963701
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fixed dose combination
Study: NCT02886559
Drug: Chidamide plus DCAG regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: chidamide, decitabine, aclarubicin, cytarabine and G-CSF
Study: NCT03704181
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo twice day for one year
Study: NCT01181258
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 60 mg/kg administered intravenously (IV) for 2 hours on day -5 after Fludarabine.
Study: NCT00696969
Drug: Ambisome and Paromomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambisome 5 mg/kg single dose + Paromomycin Sulphate 15mg/kg/day for 10 days
Study: NCT00696969
Drug: Miltefosine and Paromomycin
Normalized name: Miltefosine
DrugBank: Miltefosine (DB09031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Miltefosine (standard dose) and Paromomycin Sulphate 15mg/kg/day for 10 days
Study: NCT00752726
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive
Study: NCT00547521
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants who were currently receiving methotrexate at a stable dose ≥ 10 mg for at least 4 weeks
Study: NCT03875664
Drug: Placebo - injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injectable normal saline solution
Study: NCT00629473
Drug: NPI-0052 on Days 1, 8, 15 every 28 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPI-0052 dose ranging from 0.1 to 0.9 mg/m2 NPI-0052 IV injection over 1 to 120 minutes on Days 1, 8, and 15 of 4-week cycles
Study: NCT00629473
Drug: NPI-0052 on Days 1, 4, 8, 11 every 21 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPI-0052 dose ranging from 0.075 to 0.6 mg/m2 NPI-0052 IV injection over 1 to 120 minutes on Days 1, 4, 8, and 11 of 3-week cycles
Study: NCT00670228
Drug: Standard Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard insulin therapy titrated to blood sugar control
Study: NCT03042260
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablets, 3 times a week, for a minimum of 6 months and maximum of 1 year.
Study: NCT00528996
Drug: BEA 2180 BR
Normalized name: Respa-BR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution
Study: NCT00528996
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution
Study: NCT02379468
Drug: Pedyphar Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02913768
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01756118
Drug: BEZ235
Approvals — FDA: no, EMA: no, PMDA: no
Description: A minimum of 3 dose levels
Study: NCT01099436
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01099436
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01099436
Drug: zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02081599
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03404622
Drug: IUCD
Normalized name: Intrauterine contraceptive device (IUCD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IUCD will be inserted in 100 women post placental removal and will be inserted in anther 100 women after six weeks post cesarean delivery
Study: NCT01469065
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of PF-04991532 Matching Placebo; given twice a day (BID) for 14 days
Study: NCT00700583
Drug: combination therapy of terazosin and hydrochlorothiazide
Normalized name: combinations of levothyroxine and liothyronine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg of hydrochlorothiazide eight hours before bedtime and 4 mg of terazosin at bedtime for 4 weeks
Study: NCT03917134
Drug: cephalosporin + Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: administration of cephalosporin in doses of 2 grams administered intravenously before surgery and vaginal ovules of placebo twice a day for 5 days after performing laparoscopic hysterectomy
Study: NCT00006094
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04673916
Drug: Healing evaluation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatments were topically applied for 5 days
Study: NCT01441427
Drug: recombinant human G-CSF, and rhEPO
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF 4.5 microgram /kg/day enteral EPO 88 mIU/kg/day enteral
Study: NCT01441427
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: distilled water :1 ml distilled water administered by an orogastric tube till the enteral intake reached 100 mL/kg of milk, or after a maximum of seven days.
Study: NCT03244228
Drug: HTL0016878
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution
Study: NCT03244228
Drug: Placebo - Concentrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT00647192
Drug: Eplerenone
Normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg per day
Study: NCT00647192
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg per day
Study: NCT01566578
Drug: Human recombinant epidermal growth factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical
Study: NCT02506660
Drug: Intravenous saline
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02506660
Drug: Perineural saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline in nerve block
Study: NCT00773890
Drug: TRF-1101
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily treatment with 300 mg orally for 12 weeks
Study: NCT00773890
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily treatment with TRF-1101 vehicle for 12 weeks
Study: NCT01331928
Drug: Capecitabine (Xeloda, Roche), Oxaliplatin (Sanofi-Aventis), Docetaxel (Sanofi-Aventis)
Approvals — FDA: no, EMA: no, PMDA: no
Description: capecitabine orally 1000 mg/m2 twice daily, day1 to day 10, every 2 weeks plus oxaliplatin 85mg/m2 (2hrs IV infusion)on day1, every 2 weeks for 6 cycles, then shift to docetaxel 30 mg/m2(over 30-minute intravenous infusion) on day 1 and day 8 plus oral capecitabine 825 mg/m2 twice daily on day 1 to 14, every 3 weeks for 4 cycles.
Study: NCT01659099
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: in ACBVP : 75 mg/m² on D1 in CHOP : 50 mg/m² on D1
Study: NCT01659099
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: in ACBVP : 1200 mg/m² on D1 in CHOP : 750 mg/m² on D1
Study: NCT02066415
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered once a month subcutaneously by authorized investigational site study staff.
Study: NCT02652416
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT00789633
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo given orally twice daily
Study: NCT03446417
Drug: ZN-e4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose, tablet, daily dosing
Study: NCT04185415
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Pharmaceutical Form: Solution for infusion~* Concentration: 0.9% w/v sodium chloride aqueous solution~* Route of Administration: Intravenous
Study: NCT02220751
Drug: non-surgical periodontal therapy + systemic doxycycline
Approvals — FDA: no, EMA: no, PMDA: no
Description: A program of plaque control with dental prophylaxis and oral hygiene instruction, and the scaling and root planning sessions were included in the non-surgical periodontal therapy. The scaling and root planning was performed by the same operator using curettes and an ultrasonic device, and it was inspected for a second operator. Oral hygiene was reviewed after a week and after a month of periodontal disinfection, followed by dental prophylaxis.~Non-surgical periodontal therapy was associated with systemic doxycycline 100 mg/day, for two weeks after an initial dose of 200 mg, started on the day before the first scaling and root planning session. Patients of the PD group had no access to information about antibiotics administration to patients of the PD+DM group.
Study: NCT02792998
Drug: IW-1701
Approvals — FDA: no, EMA: no, PMDA: no
Description: IW-1701 Tablet
Study: NCT02792998
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo Tablet
Study: NCT01369186
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. bolus injection
Study: NCT00821912
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1650 mg/m2 /day orally b.i.d., day 1-14 every 3 weeks.
Study: NCT01793259
Drug: methotrexate prefilled pen
Normalized name: methotrexate Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01793259
Drug: methotrexate prefilled syringe
Normalized name: methotrexate Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04025177
Drug: Indomethacin Injection
Normalized name: indomethacin Injection
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The dose of indomethacin will be 0.1 mg/kg/dose, based on birth weight, intravenously every 24 hours for a total of 3 doses. Doses 2 and 3 may be administered between 23.5 and 24.5 hours after the previous dose. Doses will be rounded to two significant figures.
Study: NCT01302054
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo for fesoterodine 4 and 8 mg for a total of 12 weeks.
Study: NCT04569994
Drug: NNC0363-0845
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose administered s.c. (subcutaneously, under the skin)
Study: NCT02063997
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets once daily for 12 weeks
Study: NCT04569994
Drug: Placebo (NNC0363-0845)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose administered s.c.
Study: NCT04498351
Drug: Control Test
Normalized name: CHEK-STIX URINALYSIS CONTROL TEST STRIP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spermatic cord block by18ml levobupivacaine 0.5% plus 2 ml normal saline in total volume of 20 ml.~The procedure is repeated on the contralateral side.
Study: NCT04630522
Drug: Drug: JMT103- 120 mg SC Q4W
Approvals — FDA: no, EMA: no, PMDA: no
Description: JMT103 is administered subcutaneously at a dose of 120 mg on day 1 of each 4-week cycle.
Study: NCT04630522
Drug: Drug: JMT103- 120 mg SC Q8W
Approvals — FDA: no, EMA: no, PMDA: no
Description: JMT103 is administered subcutaneously at a dose of 120 mg on day 1 of each 8-week cycle.
Study: NCT04630522
Drug: Drug: JMT103- 180 mg SC Q8W
Approvals — FDA: no, EMA: no, PMDA: no
Description: JMT103 is administered subcutaneously at a dose of 180 mg on day 1 of each 8-week cycle.
Study: NCT01873690
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% Dextrose in water
Study: NCT00290498
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arm A: Cyclophosphamide 300 mg/m\^2 by vein (IVPB) over 3 hours every 12 hours x 6 doses on Days 2-4, Cycle 1 and alternating cycles.~Arm B: Cyclophosphamide 750 mg/m² by vein day 1
Study: NCT00290498
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Arm A: Doxorubicin 50 mg/m\^2/day by vein over 15 minutes (12 hours after last dose of cyclophosphamide) on Day 5, Cycle 1 and alternating cycles.
Study: NCT00290498
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arm A: Methotrexate after finishing Rituximab, 200 mg/m2 by vein over 2 hours, then 800 mg/m2 by vein over 22 hours day 1 cycle 2.
Study: NCT00329615
Drug: Insulatard, flexpen
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00575874
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching tablets or capsule once daily for 12 weeks
Study: NCT03381417
Drug: pegcyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible patients are scheduled to receive three cycles of chemotherapy every two weeks. During each chemotherapy cycle pegfilgrastim is injected s.c. post chemotherapy application.
Study: NCT03381417
Drug: Neulastim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible patients are scheduled to receive three cycles of chemotherapy every two weeks. During each chemotherapy cycle pegfilgrastim is injected s.c. post chemotherapy application.
Study: NCT01591473
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo; 3 doses; nasal administration every 28 days
Study: NCT00517569
Drug: HAART
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highly active antiretroviral therapy; Discontinuation at 24 weeks; NB: The patients should be treated with 2 NRTIs+1 NNRTI or 2 NRTIs + 1 PI, according to the guidelines published by DHHS in the USA.
Study: NCT01856621
Drug: Seretide Diskus and charcoal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 inhalations as a single dose
Study: NCT01856621
Drug: SF Easyhaler and charcoal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 inhalations as a single dose
Study: NCT04584710
Drug: RTB101
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral RTB101 10 mg hard gelatin capsule once daily for 2 weeks
Study: NCT00908037
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo for comparison
Study: NCT04584710
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral matching placebo once daily for 2 weeks
Study: NCT01716104
Drug: Afalaza
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safety and Efficacy
Study: NCT01716104
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safety and Efficacy
Study: NCT01979939
Drug: DCV/ASV/BMS-791325
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02242357
Drug: Micardis®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02242357
Drug: Micardis® Plus
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02357420
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo given subcutaneously for 12 weeks.
Study: NCT02415309
Drug: 2 mg Melatonin
Normalized name: melatonin 2 MG
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 40 patients will randomly receive 2 mg melatonin
Study: NCT02415309
Drug: 10mg Melatonin
Normalized name: melatonin 10 MG
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 40 patients will randomly receive 10 mg melatonin
Study: NCT00758641
Drug: Corticosteroid Injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: kenacort 40 mg/ml triamcinolon acetonide
Study: NCT02460341
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo pill
Study: NCT02739516
Drug: FSH co-trigger
Approvals — FDA: no, EMA: no, PMDA: no
Description: In letrozole stimulated cycle; FSH (urofollitropin; Fostimon, IBSA, Bazel, Swiz; 75 IU amp) 150 IU injected once intramuscular when the mean ovarian follicle diameter was ≥18 mm.
Study: NCT02365571
Drug: LY3154207
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT02365571
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT03329378
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin 60 mg/m2 IV day 1
Study: NCT03329378
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 600 mg/m2 IV day 1
Study: NCT00474240
Drug: AEGR-733 5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00474240
Drug: AEGR-733 10 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00474240
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01418209
Drug: Low-dose 17-ß-estradiol with progesterone taper
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose 17-ß-estradiol oral (by mouth), 0.5 mg once per day for 8 (eight) weeks. 17-ß-estradiol is approved by the US Food and Drug Administration (FDA) and is indicated for the treatment of menopausal symptoms. ß is the Greek symbol for beta; the symbol and the word are used interchangeably. The 8 week estradiol treatment is followed by 14 days (2 weeks) of progesterone taper (as medroxy-progesterone 10 mg/day).
Study: NCT01418209
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo is an inactive pill that looks like the active medication.
Study: NCT02310997
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00663845
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT01380704
Drug: ABT-436
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: QD Days 1-7
Study: NCT01380704
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: QD Days 1-7
Study: NCT01435837
Drug: C3(200mg of caffeine; 1 L of water)
Normalized name: caffeine 200 MG [Revive brand of caffeine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ingestion of 200 mg of caffeine and 1 Liter of water after between pretest and posttest.
Study: NCT01435837
Drug: Placebo (no caffeine, no water).
Approvals — FDA: no, EMA: no, PMDA: no
Description: No ingestion of caffeine; no ingestion of water between pretest and posttest.
Study: NCT01583660
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200mg, PO.Bid, last from admission to hospital to one week after operation.
Study: NCT01583660
Drug: Acetaminophen oxycodone
Normalized name: acetaminophen / oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet(Acetaminophen 325mg oxycodone 5mg), Q6h orally take,last from admission to hospital to one week after operation.
Study: NCT00697281
Drug: OC000459
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets twice daily for 8 days~Dose level 1
Study: NCT00697281
Drug: OC000459
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets twice daily for 8 days~Dose level 2
Study: NCT00697281
Drug: OC000459
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets twice daily for 8 days~Dose level 3
Study: NCT00697281
Drug: OC000459
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets twice daily for 8 days~Dose level 4
Study: NCT00697281
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets twice daily for 8 days~Dose level 5
Study: NCT00903331
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo, once daily
Study: NCT03057470
Drug: 50% bolus insulin correction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive 50% of their usual bolus insulin correction for post-exercise hyperglycemia
Study: NCT03057470
Drug: 100% bolus insulin correction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive 100% of their usual bolus insulin correction for post-exercise hyperglycemia
Study: NCT03057470
Drug: 150% bolus insulin correction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive 150% of their usual bolus insulin correction for post-exercise hyperglycemia
Study: NCT02754960
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered (dosage, 100mg; dosage form, 25mg; frequency of administration, 1 time daily at 10 p.m)
Study: NCT01409369
Drug: RO4995819
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral dose
Study: NCT00257660
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 units
Study: NCT00211952
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00094107
Drug: Axitinib [AG-013736]
Approvals — FDA: no, EMA: no, PMDA: no
Description: VEGFR \[vascular endothelial growth factor Receptor\] and PDGFR \[Platelet-Derived Growth Factor Receptor\] inhibitor: Single agent AG-013736 starting dose 5 mg BID +/- 20% according to toxicity. Treatment until progression or unacceptable toxicity occurs.
Study: NCT01786252
Drug: Placebo Comparator (for hCG)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50ul of IVF medium (Global-trademark) to mimic hCG infusion
Study: NCT00637039
Drug: AZD8931
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolerability and Pharmacokinetics of AZD8931 in Patients with Advanced Solid Malignancies.
Study: NCT01749891
Drug: ALG 1001
Normalized name: DRESSING,BIATAIN ALG 2IN X 2IN C#3705
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who will receive three, monthly intravitreal injections of 1.5mg, 2.5mg ,or 4.0 /50μl of ALG-1001 in 0.05cc in isotonic saline solution.
Study: NCT00647660
Drug: Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80/5mg, single dose fasting
Study: NCT00647660
Drug: Corzide® Tablets 80 mg/5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80/5mg, single dose fasting
Study: NCT02409862
Drug: Placebo Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: This group will receive the single dose of 24 IU placebo, self-administered intranasally (IN). Prior to administration a saliva sampling will be done. Afterwards, they will participate in the Choices Study during EEG and eye tracking recording.
Study: NCT00446186
Drug: Comparator: placebo / Duration of Treatment: 2 Weeks
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01167868
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablet
Study: NCT01399268
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Prepared by pharmacy, 100 mg, IV, every 8 hours, 3 times